Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has maintained a Neutral rating on Alnylam Pharmaceuticals (ALNY) and reduced the price target from $165 to $150.

February 23, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained a Neutral rating on Alnylam Pharmaceuticals and lowered the price target from $165 to $150.
The reduction in price target by Cantor Fitzgerald could lead to a negative perception among investors, potentially causing a short-term decrease in ALNY's stock price. The maintenance of a Neutral rating indicates that the analyst sees limited upside or downside potential, which might not significantly change investor sentiment but the lower price target suggests a tempered outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100